News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
593,497 Results
Type
Article (40465)
Company Profile (99)
Press Release (552925)
Multimedia
Podcasts (141)
Webinars (23)
Section
Business (170853)
Career Advice (2047)
Deals (25506)
Drug Delivery (118)
Drug Development (71471)
Employer Resources (126)
FDA (14629)
Job Trends (12283)
News (287521)
Policy (26716)
Tag
Academia (2525)
Academic (2)
Accelerated approval (19)
Adcomms (22)
Allergies (109)
Alliances (44906)
ALS (150)
Alzheimer's disease (1509)
Antibody-drug conjugate (ADC) (264)
Approvals (14817)
Artificial intelligence (467)
Autoimmune disease (115)
Automation (28)
Bankruptcy (214)
Best Places to Work (9921)
BIOSECURE Act (22)
Biosimilars (147)
Biotechnology (69)
Bladder cancer (141)
Brain cancer (51)
Breast cancer (571)
Cancer (4224)
Cardiovascular disease (351)
Career advice (1732)
Career pathing (35)
CAR-T (253)
CDC (48)
Cell therapy (681)
Cervical cancer (30)
Clinical research (60937)
Collaboration (1474)
Company closure (3)
Compensation (625)
Complete response letters (46)
COVID-19 (2381)
CRISPR (75)
C-suite (645)
Cystic fibrosis (123)
Data (5507)
Decentralized trials (2)
Denatured (42)
Depression (100)
Diabetes (449)
Diagnostics (5519)
Digital health (38)
Diversity (9)
Diversity, equity & inclusion (40)
Drug discovery (220)
Drug pricing (167)
Drug shortages (32)
Duchenne muscular dystrophy (191)
Earnings (70719)
Editorial (57)
Employer branding (16)
Employer resources (115)
Events (92085)
Executive appointments (892)
FDA (17218)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (3)
Frontotemporal dementia (18)
Funding (1238)
Gene editing (162)
Generative AI (47)
Gene therapy (522)
GLP-1 (981)
Government (3931)
Grass and pollen (6)
Guidances (359)
Healthcare (16557)
HIV (44)
Huntington's disease (34)
IgA nephropathy (68)
Immunology and inflammation (199)
Immuno-oncology (36)
Indications (74)
Infectious disease (2605)
Inflammatory bowel disease (172)
Inflation Reduction Act (14)
Influenza (93)
Intellectual property (192)
Interviews (373)
IPO (11629)
IRA (51)
Job creations (2725)
Job search strategy (1453)
Kidney cancer (9)
Labor market (61)
Layoffs (433)
Leadership (31)
Legal (6138)
Liver cancer (82)
Longevity (10)
Lung cancer (587)
Lymphoma (340)
Machine learning (30)
Management (42)
Manufacturing (633)
MASH (157)
Medical device (11099)
Medtech (11129)
Mergers & acquisitions (14769)
Metabolic disorders (1172)
Multiple sclerosis (138)
NASH (17)
Neurodegenerative disease (262)
Neuropsychiatric disorders (61)
Neuroscience (2514)
NextGen: Class of 2025 (5606)
Non-profit (4208)
Now hiring (43)
Obesity (561)
Opinion (263)
Ovarian cancer (139)
Pain (157)
Pancreatic cancer (174)
Parkinson's disease (238)
Partnered (24)
Patents (396)
Patient recruitment (375)
Peanut (45)
People (50489)
Pharmaceutical (29)
Pharmacy benefit managers (20)
Phase I (18813)
Phase II (26560)
Phase III (20431)
Pipeline (3641)
Policy (274)
Postmarket research (2459)
Preclinical (8007)
Press Release (69)
Prostate cancer (211)
Psychedelics (37)
Radiopharmaceuticals (231)
Rare diseases (658)
Real estate (5145)
Recruiting (50)
Regulatory (20184)
Reports (37)
Research institute (2296)
Resumes & cover letters (312)
Rett syndrome (24)
RNA editing (10)
RSV (71)
Schizophrenia (125)
Series A (214)
Series B (151)
Service/supplier (6)
Sickle cell disease (89)
Special edition (19)
Spinal muscular atrophy (132)
Sponsored (37)
Startups (2859)
State (1)
Stomach cancer (13)
Supply chain (96)
Tariffs (76)
The Weekly (97)
Vaccines (910)
Venture capital (63)
Weight loss (401)
Women's health (62)
Worklife (17)
Date
Today (110)
Last 7 days (494)
Last 30 days (2222)
Last 365 days (27974)
2025 (27420)
2024 (30524)
2023 (33780)
2022 (44102)
2021 (46931)
2020 (45346)
2019 (39807)
2018 (29973)
2017 (27392)
2016 (26658)
2015 (30687)
2014 (24820)
2013 (21375)
2012 (22114)
2011 (22680)
2010 (21045)
Location
Africa (738)
Alabama (79)
Alaska (6)
Arizona (197)
Arkansas (11)
Asia (39561)
Australia (5413)
California (9209)
Canada (2585)
China (1053)
Colorado (386)
Connecticut (429)
Delaware (302)
Europe (79029)
Florida (1294)
Georgia (299)
Hawaii (2)
Idaho (42)
Illinois (715)
India (56)
Indiana (425)
Iowa (20)
Japan (353)
Kansas (101)
Kentucky (33)
Louisiana (21)
Maine (38)
Maryland (1165)
Massachusetts (6802)
Michigan (275)
Minnesota (465)
Mississippi (5)
Missouri (94)
Montana (29)
Nebraska (21)
Nevada (100)
New Hampshire (54)
New Jersey (2622)
New Mexico (26)
New York (2523)
North Carolina (1203)
North Dakota (10)
Northern California (4382)
Ohio (263)
Oklahoma (20)
Oregon (33)
Pennsylvania (1807)
Puerto Rico (13)
Rhode Island (45)
South America (1022)
South Carolina (48)
South Dakota (1)
Southern California (3619)
Tennessee (152)
Texas (1421)
United States (33061)
Utah (271)
Vermont (1)
Virginia (215)
Washington D.C. (75)
Washington State (751)
West Virginia (4)
Wisconsin (98)
Wyoming (2)
593,497 Results for "novo nordisk china r and d center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid
Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk’s unsolicited bid to acquire obesity biotech Metsera.
November 3, 2025
·
4 min read
·
Tristan Manalac
Alzheimer’s disease
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10%
“We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.
November 24, 2025
·
2 min read
·
Annalee Armstrong
Obesity
Novo’s Metsera Bid Attracts FTC Scrutiny as Pfizer Matches $10B Offer
Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera. The antitrust watchdog has spotted issues with the structure of Novo’s bid, while its New York-based rival has put more money on the table.
November 6, 2025
·
3 min read
·
Tristan Manalac
GLP-1
A Compounding Problem: How GLP-1s Drove Novo Nordisk’s Rapid Rise and Fall
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma recover?
August 13, 2025
·
5 min read
·
Nick Paul Taylor
C-suite
UPDATE: Novo Foundation Completes Board Takeover After Shareholder Pushback
“As the future chair I will attend to the interests of not only the Novo Nordisk Foundation but all shareholders of the company,” incoming chair and former Novo Nordisk CEO Lars Rebien Sørensen said at the meeting held Friday.
November 14, 2025
·
5 min read
·
Annalee Armstrong
Editorial
Novo’s CEO Doesn’t Seem To Mind Being Big Pharma’s Villian
Novo Nordisk, under new CEO Maziar Mike Doustdar, has a new attitude. It’s making Pfizer livid.
October 31, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Novo Nordisk’s sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
November 5, 2025
·
4 min read
Manufacturing
Violations at Novo’s Indiana Plant ‘Unacceptable,’ FDA Says
Slapped with the most severe post-inspection classification, the state of Novo Nordisk’s Indiana manufacturing site could pose a problem for clients, including Regeneron and Scholar Rock.
October 14, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
UPDATE: Novo Nordisk Seeks To Steal Metsera From Pfizer With $8.5B Offer
Pfizer called Novo’s offer “reckless and unprecedented,” in a statement issued Thursday morning.
October 30, 2025
·
4 min read
·
Annalee Armstrong
Obesity
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin
Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its efficacy could become even stronger with longer follow-up, according to analysts at BMO Capital Markets.
November 25, 2025
·
2 min read
·
Tristan Manalac
1 of 59,350
Next
